#Top 10 VSD Surgeries Hospitals in India

[indianhealthguru]

Ventricular septal defect (VSD) is a congenital heart condition characterized by the presence of a hole in the septum that divides the heart's lower chambers. Typically, during normal fetal development, this septal wall closes before birth, ensuring that oxygen-rich blood does not mix with oxygen-poor blood.

[kbc-78]

Why Dr. Kartik Bhosale is the Best Doctor for All Heart Disease Treatment

Heart disease is a serious and complex condition that requires expert care and treatment. Dr. Kartik Bhosale, a renowned Best cardiologist in Pune, is the best doctor for heart disease treatment. With clinics located in Wakad, Ravet, and Baner, Dr. Kartik Bhosale offers accessible and top-notch cardiac care. Here’s why he is the preferred choice for heart disease treatment:

Extensive Experience and Expertise:

Over a Decade of Experience: Dr. Bhosale has more than 10 years of experience in managing various heart diseases at an advanced level.

Prestigious Training: He completed his MBBS from the Seth G. S. Medical College and KEM Hospital, Mumbai, and his MD Medicine and DM Cardiology from the PGIMER, Dr. Ram Manohar Lohia Hospital, New Delhi, where he trained with world-renowned experts.

Advanced Qualifications:

Gold Medal in Cardiology: Dr. Bhosale has earned a Gold Medal in Cardiology, showcasing his excellence in the field.

DrNB (Cardiology): He also holds a DrNB (Cardiology) from the National Board of Examination, New Delhi.

Professional Memberships: He is a member of the Cardiological Society of India (MCSI), the National Academy of Medical Sciences (MNAMS), and the Society Of Cardiovascular Angiography And Intervention (AMSCAI).

Comprehensive Cardiac Services:

Dr. Kartik Bhosale provides a wide range of cardiac services, ensuring that all aspects of heart disease are addressed:

Diagnostic Expertise: He is proficient in performing Echocardiograms (2D ECHO), Transesophageal Echocardiography (TEE), Dobutamine Stress Echocardiography (DSE), Stress Tests (TMT), ABPM, and Holter monitoring.

Interventional Procedures: His main focus areas include Coronary Angiography and Angioplasty, Peripheral Angiography and Angioplasty, Balloon Mitral Valvotomy, Permanent Pacemaker Implantation, Device closure of ASD, VSD, and PDA, and IVC filter implantation.

Complex Interventions: Dr. Kartik Bhosale is well-versed in complex interventions such as Rota-Blation and Bifurcation stenting. He uses intracoronary imaging techniques like Intravascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT) to optimize procedures and ensure the best long-term outcomes.

Fractional Flow Reserve (FFR): He employs FFR to make precise decisions regarding the appropriateness of angioplasty.

Comprehensive Care and Emergency Management:

All-Round Cardiac Care: Dr. Kartik Bhosale is capable of managing all types of cardiac patients, including those with chronic conditions and acute emergencies such as heart attacks, heart failure, and arrhythmias.

Holistic Approach: His expertise in cardiology surgery makes him a sought-after heart specialist in the region, providing comprehensive and holistic cardiac care.

Accessible Locations:

Multiple Clinics: Dr. Kartik Bhosale’s Cardiology clinics in Wakad, Ravet, and Baner make it convenient for patients across Pune to access his services.

Consultation Availability: In addition to his own clinics, he is a consultant at Symbiosis University Hospital and Research Center Pune, Jupiter Hospital Baner, Sanjivani Vitalife Hospital, Aundh, and MIMER Medical College, Talegaon.

Patient-Centered Approach:

Personalized Care: Dr. Kartik Bhosale is known for his patient-centered approach, taking the time to understand each patient’s unique condition and needs.

Empathy and Compassion: His compassionate care and dedication to patient well-being make him highly recommended by his patients.

State-of-the-Art Facilities:

Modern Equipment: His clinics are equipped with the latest diagnostic and therapeutic technologies, ensuring high-quality care.

Innovative Treatments: Dr. Kartik Bhosale stays updated with the latest advancements in cardiology, offering innovative and effective treatment options.

Conclusion:

Dr. Kartik Bhosale’s extensive experience, advanced qualifications, comprehensive cardiac services, and patient-centered approach make him the best doctor for heart disease treatment in Pune. With clinics in Wakad, Ravet, and Baner, he ensures accessible and top-quality cardiac care for his patients. If you are seeking expert care for heart disease, consulting Dr. Kartik Bhosale is a decision you can trust for your heart health.

[indiamedicaltourism]

VSD Surgery Cost in India

Ventricular Septal Defect is simply known as VSD and this is usually found in patients right from birth. VSD is a case where the human heart has a hole in the chambers of the heart or in between the walls of the heart. VSD is more commonly observed among newly born infant kids. Some children grow healthy along with the VSD, but still, life remains risky and uncertain. The main cause of the VSD is due to abnormal development of heart chambers during gestation.

VSD symptoms are easily observed in growing kids such as the growth of kids being hindered and frequent loss the appetite. In the case of grown adults, the symptoms are like a sudden fall in weight and difficulties while doing any physical exercise.

VSD is diagnosed with plenty of techniques and the most effective method is ECG. Other techniques like X-ray, MRI, and CT scan are also used to determine VSD. In some cases, the infant recovers from VSD, and the hole gets closed, but if the case is worse when there are multiple holes in the heart then surgery might be the best option. The most common procedure adopted in treating VSD is Open heart surgery.  The VSD Surgery cost in India varies based on age. So here is a small detail about the Price of VSD Surgery in India.

VSD Surgery Cost in India

The VSD Surgery price in India ranges from Rupees 2, 00, 000 to Rupees 5, 00, 000. India has a higher success rate of VSD Surgery and the Cost of VSD Surgery in India varies on the patient's condition, age, and the hospital. Also, the other extra costs like tests, diagnoses, admission fees, medication, injections, and much more.

Best VSD Surgery Hospitals in India

Medanta the Medicity is the Best VSD Surgery hospital in India. The hospital is situated in Gurgaon and the hospital has treated numerous VSD patients.

BLK Super Specialty Hospital in New Delhi is one of the Best hospitals for VSD Surgery in India. Also, this hospital is one of the prestigious healthcare centers in India.

Indraprastha Apollo Hospital in New Delhi is a well-known hospital and has treated patients suffering from VSD.

Best VSD Surgery Doctors in India

Dr. Naresh Trehan is one of the Best VSD Surgery doctors in India. He has more than 40 years of experience in health care centers, and currently, he is working at Medanta Hospital, Gurgaon.

Dr. Rajesh Sharma is the Best Doctor for VSD Surgery in India with more than 32 years of experience in dealing with VSD patients. He is working at Apollo Hospital Indraprastha, New Delhi.

Dr. Murtaza Ahmed Chishti is a well-known surgeon and has cured many patients suffering from VSD. He is practicing at Artemis Hospital in Gurgaon.

Al AfiyaMedi Tour is a leading medical tourism company in India.  We are offer medical tourism services in India foreign patients. Some of the main countries are Bangladesh, south Africa, Uganda, Zambia, Namibia, Iraq, Kenya, Nigeria and so on. We provide free assistance for TURP surgery cost in India, lung cancer treatment, breast cancer surgery cost, stomach cancer treatment in India, liver transplant cost, best hospital for heart valve replacement, bone marrow transplant cost, arthroscopic surgery, best liver transplant hospital, brain tumor surgery cost in India, kidney transplant cost, liver cancer treatment, best bone marrow hospital etc.  If you are searching for free medical and healthcare consulting to find the best hospitals and top doctors and surgeons in India for any treatment then contact us- Alafiyameditour.com.

Source: https://alafiyameditour1.blogspot.com/2023/10/vsd-surgery-cost-in-india.html

[ckshospital2]

Top 10 Cardiologists in Jaipur: Experts Who Care for Your Heart

Introduction:

When it comes to matters of the heart, both figuratively and literally, it's crucial to trust the best professionals in the field. In Jaipur, the Pink City of India, there is a wealth of skilled and experienced cardiologists who provide top-notch cardiac care. In this article, we present the top 10 cardiologists in Jaipur who have earned a reputation for their expertise, compassionate care, and commitment to improving heart health.

List of Top 10 cardiologist in Jaipur for a heart specialist

Dr. Prakash Chandwani

He is one of the most trustworthy and experienced cardiologist doctors in Jaipur.  He is excellent at diagnosing and treating cardiovascular diseases. He has immense medical knowledge and is expertise in handling Peripheral angiography & angioplasty,  Renal angiography & angioplasty,  ASD/VSD/PDA by device closer without surgical procedures,  Carotid angiography and angioplasty and EPF/ RFA and Implantation of Heart Failure Device, etc Dr. Chandwani is determined to deliver the best possible supervision to his patients. Dr. Prakaesh Chandwani is the CEO of CKS Hospital, and CKS Hospital is the best cardiology hospital in Jaipur

Services:-

Peripheral angiography & angioplasty.

Carotid angiography and angioplasty.

Bronchial Artery embolization.

Renal angiography & angioplasty.

Treat highly Calcified blockage by Rotablation.

ASD/VSD/PDA by device closer without surgery

EPF/ RFA and Implantation of Heart Failure Device

Address -: CKS Hospital F98A VKIA Road No 6, Sikar Road, Jaipur Rajasthan, India 302013

Appointment link – : https://ckshospitals.com/#appointment 

year of experience -: 20+ Years Experience Overall

Fees – 500

[robertmcase-blog]

Robert Case CEO - Medical Devices - Medtech maybe emerging market's next new thing

Emerging markets currently account for less than one-quarter of the medtech industry’s global revenues, but their share is likely to reach nearly one-third by 2022.

The medtech market in China, already the second largest in the world, is projected to grow by about 13% annually from 2015 through 2022. India’s medtech market, currently the fifth largest, could rival Japan’s and Germany’s in size by around 2022 if it continues its 17% annual growth.

Within narrow segments of the industry, emerging-market companies are already dominant. In the China market, three local companies—Biosensors International, Lepu Medical, and MicroPort—currently sell 80% of all drug-eluting stents. As recently as 2004, multinationals had a volume market share of nearly 90%. The market for direct radiography—a digital x-ray method—has also flipped in China. Local companies have taken one-half of the volume from multinationals, which had a 100% market share in 2004. In India, Transasia has become the number one supplier of in vitro diagnostic (IVD) equipment and reagents, and the company continues to spread its low-cost model to other emerging markets and even mature markets, such as Germany and the US. (About one-half of revenues originate outside of India.)

To date, local medtech companies in China have had the most success in segments that pose lower technological barriers. For example, they have grabbed 10% or less of the device market, as measured by value, in the technologically intensive fields of endoscopy and minimally invasive surgery but half or more of the market in patient monitoring and orthopedics.

As their technological skills sharpen, medtech companies in emerging markets are likely to succeed not only in their current businesses but also in new ones. Compared with multinationals, emerging-market companies have four built-in advantages: lower costs, localized products, innovative go-to-market approaches, and government support. Although these advantages are shrinking, they continue to serve as platforms for growth.

Lower Costs. Emerging-market medtech companies still have lower costs than their Western competitors.

Mindray, for example, can sell a midtier ultrasound product in China at a discount to multinational competitors while maintaining profitability and a positive customer experience, and devoting 10% of revenues to R&D.

This advantage will likely persist even as multinationals build manufacturing and R&D operations in emerging markets. For many products, local companies spend less on nonessential elements than do multinationals, which are often intent on maintaining their branding edge. For example, MRI machines built by emerging-market medtech companies are often less visually appealing because they use less expensive material and offer fewer costly bells and whistles, but their functionality is good enough for most medical practitioners.

Because lower- to midtier products are less costly to engineer, the R&D operations of emerging-market medtech companies are also less costly than those of their multinational competitors. This advantage, however, may diminish for sophisticated products developed by more expensive talent.

Localized Products. Emerging-market companies are often more successful than multinationals at tailoring their products to local needs and constraints. China’s Mindray has a presence in nearly three-quarters of all medical organizations in India. The company conducted deep customer research in India, established local operations, hired local employees, and tailored its line of patient monitoring, ultrasound, and IVD equipment to address local unmet needs. For example, it recruited local engineers and operators to provide 24/7 customer service and built a local marketing and sales team.

Emerging-market medtech companies have also found a less expensive alternative to negative-pressure wound therapy, which in mature markets is a popular way to promote the healing of acute and chronic wounds. The traditional pump- and vacuum-based therapy sold by Acelity and Smith & Nephew requires special equipment, which can cost more than $10,000 a unit, and a dressing that costs nearly $900, yet the procedures are not covered by most public medical insurance in China.

WuHan VSD Medical Science & Technology has created an approach that makes use of the wall-suction equipment common in large hospitals in China. Hospitals need not buy the expensive pumps, medical practitioners need not carry special equipment on their rounds, and patients pay lower out-of-pocket expenses thanks to a Chinese dressing that costs about $400 less. (In response, multinationals are adjusting their product portfolios.)

Innovative Go-to-Market Approaches. Emerging-market medtech companies have found alternative routes to reach patients when multinationals have tied up traditional channels.

In India, Transasia has taken advantage of channel segmentation to become the number one IVD provider. In large metropolitan areas, the company has invested in an in-house sales force of about 400 and a service force of about 200. These reps cover more than 30,000 labs. To achieve even broader coverage, Transasia has a network of 350 non-exclusive dealers that sell small-ticket items, generate leads, and work with a group of subdealers. Transasia can afford this channel strategy because it has lower manufacturing costs than its multinational competitors, such as Abbott and Siemens.

Government Support. In many emerging markets, local medtech companies benefit from direct and indirect government support along the entire value chain. Governments often subsidize R&D, speed regulatory approvals, provide tax and financial support, encourage domestic sourcing, and provide favorable reimbursements for local companies.

Wego’s orthopedic plates to mend bone fractures, for example, are less expensive and reimbursed at a higher rate than imported products in China. Depending on the province, Wego’s reimbursement rate is 15% to 20% higher than the rate for imports. The bottom line for patients: out-of-pocket cost is anywhere from three times to nearly ten times more for an imported plate.

China’s United Imaging offers another example of government support. The company’s CT scan, MRI, and digital x-ray businesses benefit from local tendering policies that favor purchases of domestic products and use authorized lists of recommended local players.

NEXT STOP: THE WORLD

Several emerging-market medtech companies are starting to go global. In France, Germany, Italy, Spain, and the UK, Biosensors is among the largest suppliers of drug-eluting stents. Mindray is the number three supplier of patient-monitoring equipment across the key global markets of China, Japan, Europe, and the US, and Sinocare is number six in the global market for blood glucose monitoring devices.

While their market shares are relatively small today, recent history from other industries suggests that emerging-market companies are adept at playing catch-up. (In pharmaceuticals, emerging-market companies have increased their share of global revenues—as measured by the industry’s top 100 companies—by a factor of 26 from 2005 through 2014.) How will medtech companies do it?

External Growth. MicroPort, a Chinese company founded in 1998 to sell stents and other cardiovascular devices, broke onto the world stage in early 2014 when it closed its acquisition of the orthopedic implant business of the US’s Wright Medical for $290 million. The acquisition tripled the size of MicroPort, which now has about 3,000 employees (one-third of them overseas) and recorded first-half 2016 revenues of nearly $199 million. The Wright acquisition also gave MicroPort a US platform on which to expand its non-orthopedic business.

India’s Transasia has made more than ten overseas acquisitions—in the Czech Republic, France, Germany, Italy, Russia, Turkey, the UK, and the US—and exports to more than 100 countries.

Organic Growth. Meanwhile, Biosensors International, based in Singapore but owned by China’s state-owned CITIC Private Equity Funds Management, has focused on organic growth to fuel its expansion. It competes against Abbott, Boston Scientific, and Medtronic in selling stents and other products. Notably, Biosensors does not rely on cost advantage. It has invested in clinical trials and in building relationships with physicians and other influencers. In response to market demands, it has also established a direct sales force in several European countries.

Innovation-Led Growth. Increasingly, emerging-market medtech companies are investing in innovation as part of their growth strategies. They recognize that there are limits to what they can achieve simply by providing low-cost, good-enough products. Mindray, for example, consistently spends more than 10% of revenues on R&D, while BGI, China’s largest gene-sequencing operator and equipment maker, devotes more than one-third of its revenues to R&D, double that of its competitor Illumina.

Given their relatively modest revenues and market value, these companies might seem like the mice that roared. Mindray, the largest of the lot, went private in early 2016 in a transaction valued at $3.3 billion. By contrast, Medtronic, the largest pure-play medtech company, has a market capitalization that exceeds $110 billion, and other competitors with nondevice businesses, such as Johnson & Johnson, are even larger.

Nevertheless, these emerging-market companies do have the opportunity to build share in narrow slices of the fragmented industry, to make bold acquisitions, and to diversify into related medtech segments. Multinationals ignore them at their peril.

HOW MULTINATIONALS SHOULD RESPOND

Many multinational medtech companies are not standing still in the face of the challenge from their low-profile, emerging-market competitors. Learning from the examples of their peers, other multinationals should respond by adapting their product portfolio, reducing costs, localizing their go-to-market approach, and acquiring emerging-market competitors.

Adapting the Product Portfolio. Many multinationals have not yet tailored their product line to the specific needs of emerging markets. The typical multinational medtech product may be too expensive, complex to operate, or encumbered with unneeded bells and whistles. But it would be a mistake simply to produce a dumbed-down version of the standard product line without addressing other elements of the business.

Multinationals need to develop sophisticated customer insight capabilities in their most important emerging markets. Their R&D, business development, and marketing teams in these markets need to work closely together, possibly adopting the iterative, fast-feedback agile approach of software development teams.

GE Healthcare exemplifies this approach. The company has more than 1,000 R&D engineers and seven manufacturing facilities in China. About one-half of its products sold in China were developed in China. Its portable ultrasound devices, for example, are easy to operate and reliable in nonhospital settings, where they are often used by community doctors. One of GE’s portable devices built for China, the Vscan, has also found a home in emergency rooms and ambulances in mature markets.

GE Healthcare has committed $300 million to create its Sustainable Healthcare Solutions business, which is aimed at emerging markets. Recognizing the value of external innovation, the company has also agreed to fund a $50 million incubator that will invest in promising emerging-market health care startups, including disruptive, low-cost technologies.

Reducing Costs. Pricing and costs are top issues globally for the medtech industry, according to BCG’s 2015 commercial excellence benchmarking study. They are especially critical in emerging markets.

If they have not done so already, multinationals should expand their manufacturing and R&D footprints in emerging markets as a way to reduce costs. For products that are not labor intensive, such as stents, local manufacturing will not be a panacea, but it could still lower logistical costs and help avoid tariffs.

Additionally, product simplification should be part of multinationals’ cost strategies. For price-sensitive hospitals and health care providers, durable, no-frills products represent the best value for their limited budgets.

Leading equipment makers, such as GE and Siemens, have been manufacturing a range of products in emerging markets for decades. Their medical equipment businesses have benefited from this decision, with COGS in China lower than the global average.

Localizing the Go-to-Market Approach. Multinationals need a local approach to reaching key buyers, decision makers, and influencers. Emerging markets often have wider geographic dispersion and lower revenue per account, making the commercial economics challenging. What is routine in the West can quickly become frustratingly complex in emerging markets. Creating a winning go-to-market approach requires both strategic insight and execution on the ground.

In China, Medtronic has managed the tradeoff between reach and specialization by basing its sales strategy on city size. For large metropolitan hospitals, each Medtronic business unit has its own sales team because the customers for the products are different. In lower-tier cities, where that approach would be too costly, Medtronic incentivizes sales representatives by allowing them to sell multiple product lines. This approach works because the hospitals in such areas generally have basic needs and because the business unit teams can provide support as required. Of course, more focused companies would likely choose a simpler approach. One size does not fit all.

Acquiring Emerging-Market Competitors. M&A can be an effective strategy for multinationals. Even if they build local facilities, multinationals still may not duplicate a local company’s cost structure. FDA-certified factories and processes, for example, are costly. M&A can allow multinationals to acquire this infrastructure less expensively than they might be able to build it.

M&A can also speed time to market. Many medtech devices require several years to register with the FDA; the acquisition of a company with those registrations in place can bypass the wait. Finally, by making an acquisition, multinationals can enjoy the favorable status of local companies in tendering and requisition processes.

Several multinationals have acquired products, distribution, local R&D, and manufacturing through acquisitions. Philips, for example, acquired manufacturing capabilities when it bought Meditronics and Alpha, two Indian medical imaging companies, in 2008. Medtronic, in 2012, acquired Kanghui, China’s leading orthopedic products manufacturer, as a way to broaden both its portfolio and its channels.

Examples of successful M&A abound, but managing due diligence, cultural fit, talent retention, and integration of acquisitions is challenging. So while this approach can jump-start entry into a market, it can also backfire if not managed carefully.

The history of emerging-market companies shows us that when they set their sights on an industry, they often catch multinationals by surprise. Medtech could be the next to face an unpleasant surprise, unless multinationals learn the lessons of their peers in other industries. 

Source: bcg.com

Recommended by : ROBERT M. CASE

President / C-Suite Executive

Medical Device / Diagnostics / Pharma / Consumer

Strategy / P&L / Innovation / Restructuring / M&A / Commercialization

Palm Beach Gardens, FL

rcase31@aim.com

https://www.linkedin.com/in/rcase1/

Brady Corp / Precision Dynamics / Lifescan Inc. 

[indianhealthguru]

Ventricular septal defect commonly referred to as a "hole in the heart," is a congenital heart anomaly characterized by the presence of an opening in the septum that divides the heart's lower chambers.

[indianhealthguru]

Ventricular septal defect (VSD), also referred to as a hole in the heart, is a congenital heart disorder in which a hole forms in the wall separating the heart's lower chambers. The ventricular septal defect surgical treatment fee in India is one of the cheapest in the world.

[indiamedicaltourism]

VSD Surgery Cost in India

Ventricular Septal Defect is simply known as VSD and this is usually found in patients right from birth. VSD is a case where the human heart has a hole in the chambers of the heart or in between the walls of the heart. VSD is more commonly observed among newly born infant kids. Some children grow healthy along with the VSD, but still, life remains risky and uncertain. The main cause of the VSD is due to abnormal development of heart chambers during gestation.

VSD symptoms are easily observed in growing kids such as the growth of kids being hindered and frequent loss the appetite. In the case of grown adults, the symptoms are like a sudden fall in weight and difficulties while doing any physical exercise.

VSD is diagnosed with plenty of techniques and the most effective method is ECG. Other techniques like X-ray, MRI, and CT scan are also used to determine VSD. In some cases, the infant recovers from VSD, and the hole gets closed, but if the case is worse when there are multiple holes in the heart then surgery might be the best option. The most common procedure adopted in treating VSD is Open heart surgery.  The VSD Surgery cost in India varies based on age. So here is a small detail about the Price of VSD Surgery in India.

VSD Surgery Cost in India

The VSD Surgery price in India ranges from Rupees 2, 00, 000 to Rupees 5, 00, 000. India has a higher success rate of VSD Surgery and the Cost of VSD Surgery in India varies on the patient's condition, age, and the hospital. Also, the other extra costs like tests, diagnoses, admission fees, medication, injections, and much more.

Best VSD Surgery Hospitals in India

Medanta the Medicity is the Best VSD Surgery hospital in India. The hospital is situated in Gurgaon and the hospital has treated numerous VSD patients.

BLK Super Specialty Hospital in New Delhi is one of the Best hospitals for VSD Surgery in India. Also, this hospital is one of the prestigious healthcare centers in India.

Indraprastha Apollo Hospital in New Delhi is a well-known hospital and has treated patients suffering from VSD.

Best VSD Surgery Doctors in India

Dr. Naresh Trehan is one of the Best VSD Surgery doctors in India. He has more than 40 years of experience in health care centers, and currently, he is working at Medanta Hospital, Gurgaon.

Dr. Rajesh Sharma is the Best Doctor for VSD Surgery in India with more than 32 years of experience in dealing with VSD patients. He is working at Apollo Hospital Indraprastha, New Delhi.

Dr. Murtaza Ahmed Chishti is a well-known surgeon and has cured many patients suffering from VSD. He is practicing at Artemis Hospital in Gurgaon.

Al Afiya Medi Tour is a leading medical tourism company in India.  We are offer medical tourism services in India foreign patients. Some of the main countries are Bangladesh, south Africa, Uganda, Zambia, Namibia, Iraq, Kenya, Nigeria and so on. We provide free assistance for TURP surgery cost in India, lung cancer treatment, breast cancer surgery cost, stomach cancer treatment in India, liver transplant cost, best hospital for heart valve replacement, bone marrow transplant cost, arthroscopic surgery, best liver transplant hospital, brain tumor surgery cost in India, kidney transplant cost, liver cancer treatment,best bone marrow hospital etc.  If you are searching for free medical and healthcare consulting to find the best hospitals and top doctors and surgeons in India for any treatment then contact us- Alafiyameditour.com.

Source: https://alafiyameditour1.blogspot.com/2023/10/vsd-surgery-cost-in-india.html

[indianhealthguru]

The costs are up to 50% much less as compared to other developed countries, which make India an ideal desire for this procedure.

🌐 https://bit.ly/3CaoM8V 📞+91-9371136499 📩 contact@indianhealthguru.com

[indianhealthguru]

Ventricular septal defect surgery cost in India has gained popularity due to the cost effective procedure. They are up to 50% much less as compared to other developed countries

🌐 https://www.indianhealthguru.com/ventricular-septal-defect-surgery-India-low-cost-benefits.html 📞 +91-9371136499 📩 contact@indianhealthguru.com

[indianhealthguru]

Some of the VSD surgeons in India perceived a prosperity rate which is as high as 99% for ASD/VSD surgery.

[indianhealthguru]

The ventricular septal defect surgery India is provided at best VSD treatment hospital in India at a very high VSD surgery success rate in India which can vary between 97 to 99 %, which are well equipped with advanced types of machinery & operated by highly experienced medical professionals.